肝繊維症(Liver Fibrosis):治療薬開発パイプライン動向(2015年上半期版)

【英語タイトル】Liver Fibrosis - Pipeline Review, H1 2015

Global Markets Directが出版した調査資料(GMDHC6351IDB)・商品コード:GMDHC6351IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2015年2月28日
・ページ数:164
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥212,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥636,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における肝繊維症(Liver Fibrosis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・肝繊維症(Liver Fibrosis)の概要
・肝繊維症(Liver Fibrosis)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・肝繊維症(Liver Fibrosis)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・肝繊維症(Liver Fibrosis)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・肝繊維症(Liver Fibrosis)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Liver Fibrosis – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Liver fibrosis – Pipeline Review, H1 2015’, provides an overview of the Liver fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Liver fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Liver fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Liver fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liver fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liver fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Fibrosis Overview 7
Therapeutics Development 8
Pipeline Products for Liver Fibrosis – Overview 8
Pipeline Products for Liver Fibrosis – Comparative Analysis 9
Liver Fibrosis – Therapeutics under Development by Companies 10
Liver Fibrosis – Therapeutics under Investigation by Universities/Institutes 12
Liver Fibrosis – Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Liver Fibrosis – Products under Development by Companies 15
Liver Fibrosis – Products under Investigation by Universities/Institutes 18
Liver Fibrosis – Companies Involved in Therapeutics Development 19
Advinus Therapeutics Ltd. 19
Angion Biomedica Corp. 20
BerGenBio AS 21
BiOrion Technologies B.V. 22
Celgene Corporation 23
Digna Biotech, S.L. 24
FibroGen, Inc. 25
Galectin Therapeutics, Inc. 26
Genfit SA 27
GenKyoTex S.A. 28
Gilead Sciences, Inc. 29
GNI Group Ltd. 30
La Jolla Pharmaceutical Company 31
LG Life Sciences, Ltd. 32
Nitto Denko Corporation 33
Pharmaxis Limited 34
Promedior, Inc. 35
Promethera Biosciences S.A. 36
ProMetic Life Sciences Inc. 37
RXi Pharmaceuticals Corporation 38
TCM Biotech International Corp 39
Vascular Biogenics Ltd. 40
Virobay Inc. 41
Liver Fibrosis – Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
ANG-3281 – Drug Profile 52
ANG-3298 – Drug Profile 53
ANG-4011 – Drug Profile 54
BGB-324 – Drug Profile 55
BOT-162 – Drug Profile 56
BOT-191 – Drug Profile 57
CC-539 – Drug Profile 58
CC-90001 – Drug Profile 59
CIGB-500 – Drug Profile 60
CT-140 – Drug Profile 61
DB-036 – Drug Profile 62
DCBBO-1202 – Drug Profile 63
disitertide – Drug Profile 64
Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis – Drug Profile 66
F-351 – Drug Profile 67
FG-3019 – Drug Profile 69
GCS-100 – Drug Profile 71
GFT-505 – Drug Profile 73
GKT-137831 – Drug Profile 76
GKT-901 – Drug Profile 77
GM-CT-01 – Drug Profile 78
GM-CT-02 – Drug Profile 81
GR-MD-01 – Drug Profile 82
GR-MD-02 – Drug Profile 83
HepaStem – Drug Profile 85
KW-0 – Drug Profile 87
LC-280126 – Drug Profile 88
LJPC-201 – Drug Profile 90
melittin – Drug Profile 91
ND-L02s0201 – Drug Profile 92
NPLC-0393 – Drug Profile 94
P-17 – Drug Profile 95
PBI-4050 – Drug Profile 97
PRI-724 – Drug Profile 98
PRM-151 – Drug Profile 100
PXS-4728A – Drug Profile 102
PXS-5033A – Drug Profile 103
RXI-209 – Drug Profile 104
simtuzumab – Drug Profile 105
Small Molecule for Liver Fibrosis – Drug Profile 107
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis – Drug Profile 108
Stem Cell Therapy for Liver Fibrosis and Liver Diseases – Drug Profile 109
Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology – Drug Profile 110
TCM-808FB – Drug Profile 111
TGFTX-4 Program – Drug Profile 112
VB-201 – Drug Profile 113
VBY-376 – Drug Profile 115
VBY-825 – Drug Profile 116
Liver Fibrosis – Recent Pipeline Updates 117
Liver Fibrosis – Dormant Projects 150
Liver Fibrosis – Discontinued Products 151
Liver Fibrosis – Product Development Milestones 152
Featured News & Press Releases 152
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160

[List of Tables]
Number of Products under Development for Liver Fibrosis, H1 2015 12
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Development by Companies, H1 2015 (Contd..2) 21
Products under Investigation by Universities/Institutes, H1 2015 22
Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd., H1 2015 23
Liver Fibrosis - Pipeline by Angion Biomedica Corp., H1 2015 24
Liver Fibrosis - Pipeline by BerGenBio AS, H1 2015 25
Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2015 26
Liver Fibrosis - Pipeline by Celgene Corporation, H1 2015 27
Liver Fibrosis - Pipeline by Digna Biotech, S.L., H1 2015 28
Liver Fibrosis - Pipeline by FibroGen, Inc., H1 2015 29
Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2015 30
Liver Fibrosis - Pipeline by Genfit SA, H1 2015 31
Liver Fibrosis - Pipeline by GenKyoTex S.A., H1 2015 32
Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H1 2015 33
Liver Fibrosis - Pipeline by GNI Group Ltd., H1 2015 34
Liver Fibrosis - Pipeline by La Jolla Pharmaceutical Company, H1 2015 35
Liver Fibrosis - Pipeline by LG Life Sciences, Ltd., H1 2015 36
Liver Fibrosis - Pipeline by Nitto Denko Corporation, H1 2015 37
Liver Fibrosis - Pipeline by Pharmaxis Limited, H1 2015 38
Liver Fibrosis - Pipeline by Promedior, Inc., H1 2015 39
Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H1 2015 40
Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2015 41
Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H1 2015 42
Liver Fibrosis - Pipeline by TCM Biotech International Corp, H1 2015 43
Liver Fibrosis - Pipeline by Vascular Biogenics Ltd., H1 2015 44
Liver Fibrosis - Pipeline by Virobay Inc., H1 2015 45
Assessment by Monotherapy Products, H1 2015 46
Number of Products by Stage and Target, H1 2015 48
Number of Products by Stage and Mechanism of Action, H1 2015 51
Number of Products by Stage and Route of Administration, H1 2015 53
Number of Products by Stage and Molecule Type, H1 2015 55
Liver Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015 121
Liver Fibrosis - Dormant Projects, H1 2015 154
Liver Fibrosis - Discontinued Products, H1 2015 155

[List of Figures]
Number of Products under Development for Liver Fibrosis, H1 2015 12
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Products, H1 2015 18
Assessment by Monotherapy Products, H1 2015 46
Number of Products by Top 10 Targets, H1 2015 47
Number of Products by Stage and Top 10 Targets, H1 2015 47
Number of Products by Top 10 Mechanism of Actions, H1 2015 50
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 50
Number of Products by Top 10 Routes of Administration, H1 2015 52
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 53
Number of Products by Top 10 Molecule Types, H1 2015 54
Number of Products by Stage and Top 10 Molecule Types, H1 2015 54

【掲載企業】

Advinus Therapeutics Ltd.
Angion Biomedica Corp.
BerGenBio AS
BiOrion Technologies B.V.
Celgene Corporation
Digna Biotech, S.L.
FibroGen, Inc.
Galectin Therapeutics, Inc.
Genfit SA
GenKyoTex S.A.
Gilead Sciences, Inc.
GNI Group Ltd.
La Jolla Pharmaceutical Company
LG Life Sciences, Ltd.
Nitto Denko Corporation
Pharmaxis Limited
Promedior, Inc.
Promethera Biosciences S.A.
ProMetic Life Sciences Inc.
RXi Pharmaceuticals Corporation
TCM Biotech International Corp
Vascular Biogenics Ltd.
Virobay Inc.

★調査レポート[肝繊維症(Liver Fibrosis):治療薬開発パイプライン動向(2015年上半期版)] (コード:GMDHC6351IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[肝繊維症(Liver Fibrosis):治療薬開発パイプライン動向(2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆